Literature DB >> 33541387

X-change symposium: status and future of modern radiation oncology-from technology to biology.

Stefanie Corradini1, Maximilian Niyazi2, Dirk Verellen3, Vincenzo Valentini4, Seán Walsh5, Anca-L Grosu6,7, Kirsten Lauber2, Amato Giaccia8, Kristian Unger9, Jürgen Debus10, Bradley R Pieters11, Matthias Guckenberger12, Suresh Senan13, Wilfried Budach14, Roland Rad15, Julia Mayerle16, Claus Belka2.   

Abstract

Future radiation oncology encompasses a broad spectrum of topics ranging from modern clinical trial design to treatment and imaging technology and biology. In more detail, the application of hybrid MRI devices in modern image-guided radiotherapy; the emerging field of radiomics; the role of molecular imaging using positron emission tomography and its integration into clinical routine; radiation biology with its future perspectives, the role of molecular signatures in prognostic modelling; as well as special treatment modalities such as brachytherapy or proton beam therapy are areas of rapid development. More clinically, radiation oncology will certainly find an important role in the management of oligometastasis. The treatment spectrum will also be widened by the rational integration of modern systemic targeted or immune therapies into multimodal treatment strategies. All these developments will require a concise rethinking of clinical trial design. This article reviews the current status and the potential developments in the field of radiation oncology as discussed by a panel of European and international experts sharing their vision during the "X-Change" symposium, held in July 2019 in Munich (Germany).

Entities:  

Mesh:

Year:  2021        PMID: 33541387      PMCID: PMC7863262          DOI: 10.1186/s13014-021-01758-w

Source DB:  PubMed          Journal:  Radiat Oncol        ISSN: 1748-717X            Impact factor:   4.309


  148 in total

1.  Local tumor control probability modeling of primary and secondary lung tumors in stereotactic body radiotherapy.

Authors:  Matthias Guckenberger; Rainer J Klement; Michael Allgäuer; Nicolaus Andratschke; Oliver Blanck; Judit Boda-Heggemann; Karin Dieckmann; Marciana Duma; Iris Ernst; Ute Ganswindt; Peter Hass; Christoph Henkenberens; Richard Holy; Detlef Imhoff; Henning K Kahl; Robert Krempien; Fabian Lohaus; Ursula Nestle; Meinhard Nevinny-Stickel; Cordula Petersen; Sabine Semrau; Jan Streblow; Thomas G Wendt; Andrea Wittig; Michael Flentje; Florian Sterzing
Journal:  Radiother Oncol       Date:  2015-09-15       Impact factor: 6.280

2.  Comparison of biologically equivalent dose-volume parameters for the treatment of prostate cancer with concomitant boost IMRT versus IMRT combined with brachytherapy.

Authors:  Bradley R Pieters; Jeroen B van de Kamer; Yvonne R J van Herten; Niek van Wieringen; Greet M D'Olieslager; Uulke A van der Heide; Caro C E Koning
Journal:  Radiother Oncol       Date:  2008-04-02       Impact factor: 6.280

3.  Integration of PET-imaging into radiotherapy treatment planning for low-grade meningiomas improves outcome.

Authors:  Kerstin A Kessel; Wolfgang Weber; Igor Yakushev; Hanna Fischer; Theresa Voglhuber; Christian Diehl; Christoph Straube; Claus Zimmer; Benedikt Wiestler; Jens Gempt; Bernhard Meyer; Stephanie E Combs
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-22       Impact factor: 9.236

4.  Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy.

Authors:  Martin-Immanuel Bittner; Nicole Wiedenmann; Sabine Bucher; Michael Hentschel; Michael Mix; Wolfgang A Weber; Anca-Ligia Grosu
Journal:  Radiother Oncol       Date:  2013-07-10       Impact factor: 6.280

5.  A 4-miRNA signature predicts the therapeutic outcome of glioblastoma.

Authors:  Maximilian Niyazi; Adriana Pitea; Michel Mittelbronn; Joachim Steinbach; Carsten Sticht; Franz Zehentmayr; Daniel Piehlmaier; Horst Zitzelsberger; Ute Ganswindt; Claus Rödel; Kirsten Lauber; Claus Belka; Kristian Unger
Journal:  Oncotarget       Date:  2016-07-19

6.  Mutations in an Innate Immunity Pathway Are Associated with Poor Overall Survival Outcomes and Hypoxic Signaling in Cancer.

Authors:  Monica M Olcina; Nikolas G Balanis; Ryan K Kim; B Arman Aksoy; Julia Kodysh; Michael J Thompson; Jeff Hammerbacher; Thomas G Graeber; Amato J Giaccia
Journal:  Cell Rep       Date:  2018-12-26       Impact factor: 9.423

Review 7.  MR-guidance in clinical reality: current treatment challenges and future perspectives.

Authors:  S Corradini; F Alongi; N Andratschke; C Belka; L Boldrini; F Cellini; J Debus; M Guckenberger; J Hörner-Rieber; F J Lagerwaard; R Mazzola; M A Palacios; M E P Philippens; C P J Raaijmakers; C H J Terhaard; V Valentini; M Niyazi
Journal:  Radiat Oncol       Date:  2019-06-03       Impact factor: 3.481

8.  Prognostic values of mid-radiotherapy 18F-FDG PET/CT in patients with esophageal cancer.

Authors:  Nalee Kim; Hojin Cho; Mijin Yun; Kyung Ran Park; Chang Geol Lee
Journal:  Radiat Oncol       Date:  2019-02-04       Impact factor: 3.481

9.  Release of monocyte migration signals by breast cancer cell lines after ablative and fractionated γ-irradiation.

Authors:  Roman Hennel; Nikko Brix; Karin Seidl; Anne Ernst; Heike Scheithauer; Claus Belka; Kirsten Lauber
Journal:  Radiat Oncol       Date:  2014-03-26       Impact factor: 3.481

10.  Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in Glioblastoma.

Authors:  Patrick Grossmann; David A Gutman; William D Dunn; Chad A Holder; Hugo J W L Aerts
Journal:  BMC Cancer       Date:  2016-08-08       Impact factor: 4.430

View more
  1 in total

1.  Development of a model for fibroblast-led collective migration from breast cancer cell spheroids to study radiation effects on invasiveness.

Authors:  Jia Mei; Claudia Böhland; Anika Geiger; Iris Baur; Kristina Berner; Steffen Heuer; Xue Liu; Laura Mataite; M Camila Melo-Narváez; Erdem Özkaya; Anna Rupp; Christian Siebenwirth; Felix Thoma; Matthias F Kling; Anna A Friedl
Journal:  Radiat Oncol       Date:  2021-08-19       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.